PMC:7195088 / 32366-32604 JSONTXT

{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":133,"end":139},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T166","span":{"begin":122,"end":139},"obj":"Disease"},{"id":"T167","span":{"begin":133,"end":139},"obj":"Disease"},{"id":"T168","span":{"begin":144,"end":152},"obj":"Disease"}],"attributes":[{"id":"A166","pred":"mondo_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/MONDO_0024880"},{"id":"A167","pred":"mondo_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A168","pred":"mondo_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T182","span":{"begin":159,"end":164},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T437","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"T438","span":{"begin":46,"end":57},"obj":"Chemical"},{"id":"T439","span":{"begin":159,"end":164},"obj":"Chemical"}],"attributes":[{"id":"A437","pred":"chebi_id","subj":"T437","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A438","pred":"chebi_id","subj":"T438","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A439","pred":"chebi_id","subj":"T439","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival."}

{"project":"LitCovid-sentences","denotations":[{"id":"T258","span":{"begin":154,"end":203},"obj":"Sentence"},{"id":"T259","span":{"begin":204,"end":221},"obj":"Sentence"},{"id":"T260","span":{"begin":222,"end":238},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of chloroquine analog (GNS651) vs. tocilizumab vs. nivolumab vs. standard of care in patients with advanced or metastatic cancer and COVID-19. Open-label RCT (NCT04333914, not yet recruiting). Primary endpoint: 28-day survival."}